Home |  My Orders |  About Rittenhouse |  Browse Categories |  Advanced Search | Search:   GO! 
Book Detail
All prices are approximate and are subject to change.
Medicine > Biology
HMGB1: Functions, Inhibitors and Clinical Significance
Taskin, S. T. K. Eylem Ed.
ISBN 10: 
9798886974089
Category: 
Biology
Edition: 
1
Publisher: 
Nova Science Publishers, Inc.
Format: 
Cloth
Status: 
Active
Pages: 
280
Weight: 
2
Retail Price: 
160.00
Quantity On Hand: 
0
Quantity On Order: 
0
Email | Print

Synopsis:
Damage-associated molecular patterns (DAMPs), a term also known as alarmins coined by Walter G. Land, Seong, and Matzinger, are endogenous danger molecules that are released from damaged or dying cells and activate the innate immune system by interacting with pattern recognition receptors (PRRs). One of the most well-known DAMPs is high mobility group box-1 (HMGB1), the name being such due to its very fast movement in gel electrophoresis. Importantly, HMGB1 has been shown to contribute to the pathogenesis of various diseases including myocardial ischemia/reperfusion injury, epilepsy, diabetes, multiple sclerosis, cancer, as well as hepatic steatosis, and fatty liver disease. There are three sections in the book. The first section is named HMGB1 and Cancer, including two chapters. One of the chapters in the first section is focused on HMGB1 in cancer therapy and managing COVID-19 infection, as well as multiple sclerosis. The second chapter in the first section is the crosstalk between cancer and myocardial ischemia/reperfusion injury (MIR) through HMGB1 via ferroptotic cell death. The second section is HMGB1 and metabolic interactions, consisting of two chapters. The first chapter is HMGB1 and inflammation in adipose tissue, resulting in insulin resistance and type 2 diabetes.The second chapter in the second section sums up recent data related to HMGB1 and liver injury, e.g., drug-induced liver injury, alcoholic liver disease, non-alcoholic fatty liver disease, viral hepatitis, sepsis, and acute chronic liver failure, hepatocellular death through oxidative stress, inflammatory signaling, and autophagy in hepatocytes. The third section is about HMGB1 and neurodegenerative diseases. The section contains four chapters. The first chapter in the section evaluates HMGB1 and its antagonist in brain disorders, including epilepsy, headache, neuroimmunological disorders, neurodegenerative disorders, and stroke. The second chapter in the third sect

2010 - 2024 © Rittenhouse Book Distributors, Inc. 511 Feheley Drive, King of Prussia, PA 19406 | P: 800-345-6425 | F: 800-223-7488 |